0001398733-26-000030
SEC filingRevenue accelerated 65.7% to $14.4M with gross margin expanding to 76.0%, driving operating loss down 78.3% to -$4.2M due to favorable product mix and lower clinical trial costs, though cash burn continued amid pipeline progress.
Revenue increased 65.7% to $14.4 million in Q1 2026 from $8.7 million in the prior year, primarily driven by higher manufacturing volumes with key customer Indivior, on which a substantial portion of revenues remains dependent. This growth, expected to continue, underscores the company's reliance on licensing, manufacturing, and sales to this partner, which could delay cash flow generation if timelines shift.
Gross profit rose 116.6% to $11.0 million, expanding the gross margin to 76.0% from the prior period. The decrease in manufacture and supply costs stemmed from changes in product mix, with costs influenced by market pricing of raw materials, direct labor requirements, and allocation of fixed overhead tied to production volume. Production efficiency, measured by the cost of a salable unit, also played a role. These dynamics position the company to manage costs amid potential volume growth in products like Suboxone and Ondif, though scaling would require additional personnel.
Operating income improved markedly, with the loss narrowing 78.3% to -$4.2 million from -$19.4 million, yielding an operating margin of -29.1%. This reflects better gross profitability and controlled operating expenses. Research and development expenses decreased primarily due to lower clinical trial costs for the Anaphylm program, partially offset by higher R&D personnel costs. The company plans NDA resubmission for Anaphylm in Q3 2026, subject to completing HF and PK studies and FDA response times, signaling ongoing pipeline investment.
These results highlight operational leverage from product mix shifts and R&D efficiencies, mitigating losses while navigating customer concentration and pipeline risks to sustain progress toward commercialization milestones.